Cited by 146Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsMedical Imaging Techniques and Applications

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease

Hunt, Aoife, Schönknecht, Peter, Henze, Marcus, Seidl, Ulrich, Haberkorn, Uwe, Schröder, Johannes·2007·Psychiatry Research: Neuroimaging

DOI 10.1016/j.pscychresns.2006.12.003

Open this paper in CoChat — free account

Abstract

While significantly reduced glucose metabolism in fronto-temporo-parietal and cingulate cortices has been demonstrated in Alzheimer's disease (AD) compared with controls, cerebral glucose metabolism in patients with mild cognitive impairment who subsequently develop AD is less well-defined. In the present study we measured cerebral glucose metabolism by positron emission tomography (PET) with (18)F-2-fluoro-2-deoxy-D-glucose in 14 patients with aging-associated cognitive decline (AACD), 44 patients with AD, and 14 healthy control subjects at baseline. The AACD patients were clinically followed up, and conversion to AD was determined. Compared with controls, AACD patients had significantly reduced glucose metabolism in the right precuneus, posterior cingulate, right angular gyrus, and bilateral middle temporal cortices, while the respective deficits were more pronounced in AD patients and also involved the frontal cortices. AACD patients who subsequently converted to AD (AACD-converters) showed more extended metabolic changes which also involved the frontal and temporal cortices, right cingulate gyrus, right thalamus, and bilateral precuneus.

Integrity signals

Registry

Crossref · 10.1016/j.pscychresns.2006.12.003

Cites

0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Preclinical prediction of Alzheimer's disease using SPECT
Johnson, K. A., Jones, K., Holman, B. L., Becker, J. A., Spiers, P. A., Satlin, A., & Albert, M. S. (1998) · Neurology · doi:10.1212/wnl.50.6.1563 · Cited by 471
Retrosplenial cortex (BA 29/30) hypometabolism in mild cognitive impairment (prodromal Alzheimer's disease)
Nestor, P. J., Fryer, T. D., Ikeda, M., & Hodges, J. R. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02999.x · Cited by 227

Flagged first, then by citations

Show all 4 references

Research works printed but not linked: 34

Arnaiz, 2001, Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment, NeuroReport, 12, 851, 10.1097/00001756-200103260-00045 · DOI · Paper page
Buchsbaum, 1991, Temporal and hippocampal metabolic rate during an olfactory memory task assessed by positron emission tomography in patients with dementia of the Alzheimer type and controls. Preliminary studies, Archives of General Psychiatry, 48, 840, 10.1001/archpsyc.1991.01810330064010 · DOI
Chételat, 2003, Mild cognitive impairment. Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?, Neurology, 60, 1374, 10.1212/01.WNL.0000055847.17752.E6 · DOI
De Leon, 2001, Prediction of cognitive decline in normal elderly subjects with 2-(18F)-fluoro-2-deoxy-d-glucose/positron-emission-tomography (FDG/PET), Proceedings of the National Academy of Sciences of the United States of America, 98, 10966, 10.1073/pnas.191044198 · DOI · Paper page
De Santi, 2001, Hippocampal formation glucose metabolism and volume losses in MCI and AD, Neurobiology of Aging, 22, 529, 10.1016/S0197-4580(01)00230-5 · DOI · Paper page
Drzezga, 2003, Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study, European Journal of Nuclear Medicine and Molecular Imaging, 30, 1104, 10.1007/s00259-003-1194-1 · DOI
Elias, 2000, The preclinical phase of Alzheimer disease. A 22-year prospective study of the Framingham cohort, Archives of Neurology, 57, 808, 10.1001/archneur.57.6.808 · DOI · Paper page
Encinas, 2003, Regional blood flow assessed with 99mTc_ECD SPET as a marker of progression of mild cognitive impairment to Alzheimer's disease, European Journal of Nuclear Medicine and Molecular Imaging, 30, 1473, 10.1007/s00259-003-1277-z · DOI
Folstein, 1975, ‘Mini mental state’. A practical method for grading the cognitive state of patients for the clinician, Journal of Psychiatric Research, 12, 189, 10.1016/0022-3956(75)90026-6 · DOI · Paper page
Friston, 1995, Statistical parametric maps in functional imaging: a general linear approach, Human Brain Mapping, 2, 189, 10.1002/hbm.460020402 · DOI · Paper page
Hachinski, 1975, Cerebral blood flow in dementia, Archives of Neurology, 32, 632, 10.1001/archneur.1975.00490510088009 · DOI · Paper page
Haxby, 1985, Relations between neuropsychological and cerebral metabolic asymmetries in early Alzheimer's disease, Journal of Cerebral Blood Flow and Metabolism, 5, 193, 10.1038/jcbfm.1985.25 · DOI
Herholz, 2002, Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET, NeuroImage, 17, 302, 10.1006/nimg.2002.1208 · DOI · Paper page
Hsiung, 2004, Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging, CMAJ, 171, 863, 10.1503/cmaj.1031789 · DOI
Huang, 2002, Cingulate cortex hypoperfusion predicts Alzheimer's disease in mild cognitive impairment, BMC (Biomedcentral) Neurology, 2, 9, 10.1186/1471-2377-2-9 · DOI
Ishiwata, 1998, Cerebral blood flow of patients with age-associated memory impairment and the early stage of Alzheimer's disease. A study by SPECT using the ARG method, Nippon Ika Daigaku Zasshi, 65, 140, 10.1272/jnms1923.65.140 · DOI
Levy, 1994, Aging-associated cognitive decline, International Psychogeriatrics, 6, 63, 10.1017/S1041610294001626 · DOI
McKhann, 1984, Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease, Neurology, 34, 939, 10.1212/WNL.34.7.939 · DOI · Paper page
Nestor, 2004, Advances in the early detection of Alzheimer's disease, Nature Medicine, 10, S34, 10.1038/nrn1433 · DOI
Okamura, 2000, Prediction of progression in patients with mild cognitive impairment using IMP-SPECT, Nippon Ronen Igakkai Zasshi, 37, 974, 10.3143/geriatrics.37.974 · DOI
Pantel, 2002, Progressive medial temporal lobe changes in Alzheimer's disease revealed by quantitative MRI: potential use for monitoring of drug-related changes, Drug Development Research, 56, 51, 10.1002/ddr.10060 · DOI
Pantel, 2003, Parahippocampal volume deficits in subjects with aging-associated cognitive decline, American Journal of Psychiatry, 160, 379, 10.1176/appi.ajp.160.2.379 · DOI
Pantel, 2004, Distribution of cerebral atrophy as assessed by magnetic resonance imaging reflects patterns of neuropsychological deficits in Alzheimer's dementia, Neuroscience Letters, 361, 17, 10.1016/j.neulet.2003.12.072 · DOI
Ravaglia, 2006, Conversion of mild cognitive impairment to dementia: predictive role of mild cognitive impairment subtypes and vascular risk factors, Dementia and Geriatric Cognitive Disorders, 21, 51, 10.1159/000089515 · DOI
Ritchie, 2001, Classification criteria for mild cognitive impairment — a population-based validation study, Neurology, 56, 37, 10.1212/WNL.56.1.37 · DOI
Scarmeas, 2004, Cognitive reserve: implications for diagnosis and prevention of Alzheimer's disease, Current Neurology and Neuroscience Reports, 4, 374, 10.1007/s11910-004-0084-7 · DOI
Schönknecht, 2003, Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy, Psychiatry Research: Neuroimaging, 120, 231, 10.1016/S0165-1781(03)00197-5 · DOI
Schönknecht, 2005, Prevalence and natural course of aging-associated cognitive decline in a population-based sample of young–old subjects, American Journal of Psychiatry, 162, 2071, 10.1176/appi.ajp.162.11.2071 · DOI
Schröder, 1998, Prevalence of mild cognitive impairment in a community sample, Journal of Neural Transmission Supplement, 54, 51, 10.1007/978-3-7091-7508-8_5 · DOI
Schröder, 2001, Patterns of cortical activity and memory performance in Alzheimer's disease, Biological Psychiatry, 49, 426, 10.1016/S0006-3223(00)00983-5 · DOI
Silverman, 2001, Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome, Journal of the American Medical Association, 286, 2110
Staffen, 2005, Brain perfusion SPECT in patients with mild cognitive impairment and Alzheimer's disease: comparison of a semiquantitative and a visual evaluation, Journal of Neural Transmission, 286, 2110
Tanaka, 2002, Regional cerebral blood flow abnormalities in nondemented patients with memory impairment, Journal of Neuroimaging, 12, 112, 10.1111/j.1552-6569.2002.tb00106.x · DOI
Winblad, 2004, Mild cognitive impairment — beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment, Journal of Internal Medicine, 256, 240, 10.1111/j.1365-2796.2004.01380.x · DOI · Paper page

Sorted by citations

The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
“…(FDG) have demonstrated that individuals diagnosed with aging-associated cognitive decline have significantly reduced glucose uptake in the right precuneus, posterior cingulate, right angular gyrus, and bilateral middle temporal cortices prior to conversion into AD (Hunt et al., 2007).”
2023 Alzheimer's disease facts and figures
(2023) · Alzheimer's & Dementia · doi:10.1002/alz.13016 · Cited by 3,212
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
“Studies using 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET) have identified reductions in glucose uptake in asymptomatic individuals with a high risk of dementi”
Method
2024 Alzheimer's disease facts and figures
(2024) · Alzheimer's & Dementia · doi:10.1002/alz.13809 · Cited by 2,536
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
2022 Alzheimer's disease facts and figures
Anonymous (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12638 · Cited by 2,469
Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease
Bell, R. D., & Zloković, B. V. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0522-3 · Cited by 883
“Studies using 2-[18F] fluoro-2-deoxy-D-glucose (FDG)PET, which measures cerebral glucose transport across the BBB, have shown reduction in cerebral glucose uptake in individuals with MCI or probable and possible AD prior to conversion to AD [26, 44].”
Method
The blood-brain barrier in Alzheimer’s disease
Zenaro, E., Piacentino, G., & Constantin, G. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.07.007 · Cited by 767
“Several studies using F-2-ﬂ uoro-2-deoxy-D -glu- cose-PET (FDG-PET) have demonstrated that MCI patients take up less glucose at the BBB, and FGD-PET may therefore be used as a marker for the preclinical diagnosis of AD (Hunt et al., 2007; Samuraki et al., 2007; Mosconi et al., 2008).”
The blood-brain barrier in aging and neurodegeneration
Knox, E. G., Aburto, M. R., Clarke, G., Cryan, J. F., & O’Driscoll, C. M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01511-z · Cited by 738
Vascular dysfunction—The disregarded partner of Alzheimer's disease
Sweeney, M. D., Montagne, A., Sagare, A. P., Nation, D. A., Schneider, L. S., Chui, H. C., Harrington, M. G., Pa, J., Law, M., Wang, D. J. J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.222 · Cited by 711
“cingulate, right angular gyrus, bilateral temporal cortices) before any detectable neurodegenerative changes, brain atrophy, and/or conversion to AD [82].”
The dynamic blood–brain barrier
Keaney, J., & Campbell, M. (2015) · The FEBS Journal · doi:10.1111/febs.13412 · Cited by 616
In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial
Gejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., Rodell, A., Brændgaard, H., Gottrup, H., Schacht, A., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00108 · Cited by 480
“Patient characteristics at baseline and 6 months are listed in Table 3.”
Background
Evidence for brain glucose dysregulation in Alzheimer's disease
An, Y., Varma, V. R., Varma, S., Casanova, R., Dammer, E. B., Pletniková, O., Chia, C. W., Egan, J. M., Ferrucci, L., Troncoso, J. C., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.09.011 · Cited by 522
Cerebral hypoperfusion and glucose hypometabolism: Key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer's disease
Daulatzai, M. A. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23777 · Cited by 440
“frontal and temporal cortices, right cingulate gyrus, right thalamus, and bilateral precuneus (Hunt et al., 2007).”
Background
Lipopolysaccharide Associates with Amyloid Plaques, Neurons and Oligodendrocytes in Alzheimer’s Disease Brain: A Review
Zhan, X., Stamova, B. S., & Sharp, F. R. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00042 · Cited by 361
“Cerebral glucose metabolism is decreased in preclinical and prodromal AD before symptoms (Hunt et al., 2007; Herholz, 2010).”
Background
Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery
Patching, S. G. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9672-6 · Cited by 376
Parietal cortex matters in Alzheimer's disease: An overview of structural, functional and metabolic findings
Jacobs, H. I. L., Van Boxtel, M. P. J., Jolles, J., Verhey, F. R. J., & Uylings, H. B. M. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.06.009 · Cited by 293
Structural and functional biomarkers of prodromal Alzheimer's disease: A high-dimensional pattern classification study
Fan, Y., Resnick, S. M., Wu, X., & Davatzikos, C. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.02.043 · Cited by 288
“…flow or metabolic activity in AD patients (Foster et al., 1983; Ishii et al., 2005b; Kawachi et al., 2006; Koss et al., 1985; Martin et al., 1986) and in elderly individuals with cognitive decline (Hunt et al., 2007); however the biological underpinnings of these asymmetries are not quite known.”
Background
Impairing the Mitochondrial Fission and Fusion Balance: A New Mechanism of Neurodegeneration
Knott, A. B., & Bossy‐Wetzel, E. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.030 · Cited by 263
The blood–brain barrier in neurodegenerative disease: a rhetorical perspective
Carvey, P. M., Hendey, B., & Monahan, A. J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06319.x · Cited by 260
“…emission tomography (PET), a measure of cerebral glucose transport across the BBB, show a reduction in cerebral glucose uptake in patients with mild cognitive decline and possible AD prior to progression to AD (Drzezga et al. 2003; Hunt et al. 2007; Bell and Zlokovic 2009).”
BackgroundResult
Neurovascular Dysfunction and Faulty Amyloid -Peptide Clearance in Alzheimer Disease
Sagare, A. P., Bell, R. D., & Zlokovic, B. V. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011452 · Cited by 251
“Several studies have suggested that reduced glucose uptake across the BBB as seen by FDG-PET can precede brain atrophy (Mosconi et al. 2006; Hunt et al. 2007; Samuraki et al. 2007; Mosconi et al. 2008; Herholz 2010) and may be used as a potential biomarker for AD (Miller 2009; Perrin et al. 2009).”
BackgroundInfluential
Glucose Transporters in Brain: In Health and in Alzheimer’s Disease
Szablewski, L. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160841 · Cited by 211
“PET imaging studies showed that altered glucose transport occurs early in AD [145].”
Impaired vascular-mediated clearance of brain amyloid beta in Alzheimer’s disease: the role, regulation and restoration of LRP1
Ramanathan, A., Nelson, A. R., Sagare, A. P., & Zlokovic, B. V. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00136 · Cited by 205
“…by positron emission tomography (PET) using a glucose analog, 18F-2-fluoro-2-deoxy-D-glucose (FDG), is reported to be a forerunner to brain atrophy (Hunt et al., 2007), and has been observed in individuals with a genetic risk for AD, with a positive familial AD history, as well as those with none…”
BackgroundMethod
Vascular contributions to cognitive impairment, clinical Alzheimer's disease, and dementia in older persons
Kapasi, A., & Schneider, J. A. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.12.023 · Cited by 221
Combining shape and connectivity analysis: An MRI study of thalamic degeneration in Alzheimer's disease
Zarei, M., Patenaude, B., Damoiseaux, J. S., Morgese, C., Smith, S. M., Matthews, P. M., Barkhof, F., Rombouts, S. A. R. B., Sanz‐Arigita, E., & Jenkinson, M. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.09.001 · Cited by 195
“The posterior IML contains fibers that mainly connect the posterior parietal, precuneus, cuneus, and posterior cingulate to the pulvinar (Brun and Englund, 1981; Hunt et al., 2007).”
Classification and evaluation strategies of auto-segmentation approaches for PET: Report of AAPM task group No. 211
Hatt, M., Lee, J. A., Schmidtlein, C. R., Naqa, I. E., Caldwell, C., Bernardi, E. D., Lü, W., Das, S. K., Geets, X., Grégoire, V., et al. (2017) · Medical Physics · doi:10.1002/mp.12124 · Cited by 208
Relative Intake of Macronutrients Impacts Risk of Mild Cognitive Impairment or Dementia
Roberts, R. O., Roberts, L. A., Geda, Y. E., Cha, R. H., Pankratz, V. S., O’Connor, H. M., Knopman, D. S., & Petersen, R. C. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120862 · Cited by 194
“neuronal integrity, and neuronal function [9–11], rela-”
Blood-Brain Glucose Transfer in Alzheimer’s disease: Effect of GLP-1 Analog Treatment
Gejl, M., Brock, B., Egefjord, L., Vang, K., Rungby, J., & Gjedde, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-17718-y · Cited by 163
The interplay among oxidative stress, brain insulin resistance and AMPK dysfunction contribute to neurodegeneration in type 2 diabetes and Alzheimer disease
Barone, E., Domenico, F. D., Marzia Perluigi, A., & Butterfield, D. A. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.09.006 · Cited by 182
Amyloid beta-induced glycogen synthase kinase 3β phosphorylated VDAC1 in Alzheimer's disease: Implications for synaptic dysfunction and neuronal damage
Reddy, P. H. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.06.012 · Cited by 147
“Their observations suggest a mechanistic link between GSK3β activation and mitochondrial damage in PC12 cells treated with Aβ25–35 [128].”
BackgroundInfluential
Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: similarities and differences
Redzic, Z. B. (2011) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-8-3 · Cited by 455
18 F-FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)
Smailagic, N., Vacante, M., Hyde, C., Martin, S., Ukoumunne, O. C., & Sachpekidis, C. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010632.pub2 · Cited by 235
Decoding microglial immunometabolism: a new frontier in Alzheimer's disease research
Jung, E. S., Choi, H., & Mook-Jung, I. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00825-0 · Cited by 124
“In AD, cerebral glucose metabolism declines significantly, a phenomenon strongly linked to cognitive impairment [119, 120].”
Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study
Morbelli, S., Piccardo, A., Villavecchia, G., Dessì, B., Brugnolo, A., Piccini, A., Caroli, A., Frisoni, G., Rodriguez, G., & Nobili, F. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1218-6 · Cited by 117
“Consistent with this hypothesis, recent papers have suggested a “compensatory response” in stable MCI patients, which fails in those who convert to AD [53, 54].”
Result
Glucose Controls Nuclear Accumulation, Promoter Binding, and Transcriptional Activity of the MondoA-Mlx Heterodimer
Peterson, C. W., Stoltzman, C. A., Sighinolfi, M. P., Han, K.-S., & Ayer, D. E. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01613-09 · Cited by 89
“However, MondoA(1-400), which contains the MCR region, lacks an identifiable DNA binding domain and cannot activate a TXNIP luciferase reporter (data not shown).”
Background
Alzheimer's Disease: The Downside of a Highly Evolved Parietal Lobe?
Bruner, E., & Jacobs, H. I. L. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122299 · Cited by 87
“Furthermore, parietal lobe alterations could also have an impact on clinical practice, as hypometabolism in the medial parietal areas is more accurate in differentiating cognitively healthy older people from early AD patients than metabolic changes in other brain regions [34, 61–63].”
Enhancement of Neurotrophic Factors in Astrocyte for Neuroprotective Effects in Brain Disorders Using Low-intensity Pulsed Ultrasound Stimulation.
Yang, F.-Y., Lu, W.-W., Lin, W.-T., Chang, C.-W., & Huang, S.-L. (2015) · Brain Stimulation · doi:10.1016/j.brs.2014.11.017 · Cited by 87
Nitric Oxide and Mitochondrial Function in Neurological Diseases
Ghasemi, M., Mayasi, Y. M., Hannoun, A., Eslami, S. M., & Carandang, R. A. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.02.017 · Cited by 93
Early Stages of Pathogenesis in Memory Impairment during Normal Senescence and Alzheimer's Disease
Daulatzai, M. A. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1374 · Cited by 82
“The most consistent hypometabolic region of the PCC was the retrosplenial cortex [20, 32,33].”
Metabolic changes in rat brain following intracerebroventricular injections of streptozotocin: A model of sporadic Alzheimer’s disease
Labak, M., Foniok, T., Kirk, D., Rushforth, D., Tomanek, B., Jasiński, A., & Grieb, P. (2010) · Acta neurochirurgica. Supplementum · doi:10.1007/978-3-211-98811-4_32 · Cited by 79
“Several observations indicate that decrease in brain regional glucose consumption occurs very early in AD ( 5 ), and is not an artifact due to increase in extracellular fluid space induced by brain atrophy but a true metabolic reduction per gram of tissue (7).”
Background
Principal component analysis of FDG PET in amnestic MCI
Nobili, F., Salmaso, D., Morbelli, S., Girtler, N., Piccardo, A., Brugnolo, A., Dessì, B., Larsson, S., Rodriguez, G., & Pagani, M. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0869-z · Cited by 78
“This finding is in keeping with those of a recent paper on age-associated cognitive decline [16] and might suggest a compensatory recruitment in LFC in MCI/ MCI patients, which fails in those who convert to AD. Therefore, the posterior cingulate seems to show a more linear metabolic reduction from normal ageing to AD…”
Result
Quintessential Risk Factors: Their Role in Promoting Cognitive Dysfunction and Alzheimer’s Disease
Daulatzai, M. A. (2012) · Neurochemical Research · doi:10.1007/s11064-012-0854-6 · Cited by 70
“AACD patients who subsequently converted to AD had more extensive glucose hypometabolic changes; in the frontal and temporal cortices, right cingulate gyrus, right thalamus, and bilateral precuneus [230, 232, 233].”
Background
Interactions between glial cells and the blood-brain barrier and their role in Alzheimer's disease
Zhao, M., Jiang, X., Zhang, H., Sun, J., Pei, H., Ma, L., Cao, Y., & Li, H. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101483 · Cited by 86
Glyceraldehyde caused Alzheimer’s disease-like alterations in diagnostic marker levels in SH-SY5Y human neuroblastoma cells
Koriyama, Y., Furukawa, A., Muramatsu, M., Takino, J.-I., & Takeuchi, M. (2015) · Scientific Reports · doi:10.1038/srep13313 · Cited by 71
Changes in Thalamic Connectivity in the Early and Late Stages of Amnestic Mild Cognitive Impairment: A Resting-State Functional Magnetic Resonance Study from ADNI
Cai, S., Huang, L., Zou, J., JING, L.-L., Zhai, B., Ji, G., von Deneen, K. M., Ren, J., Ren, A., & Initiative, A. D. N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0115573 · Cited by 72
“The thalamus pulvinar has widespread connectivity with the posterior parietal lobe and the PCu, which are pathological biomarkers in AD patients [47].”
Background
Beta2-Adrenergic Receptor and Astrocyte Glucose Metabolism
Dong, J., Chen, X., Cui, M., Yu, X., Pang, Q., & Sun, J. (2012) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9742-4 · Cited by 76
Cerebrovascular plasticity: Processes that lead to changes in the architecture of brain microvessels
Bogorad, M. I., DeStefano, J. G., Linville, R. M., Wong, A. D., & Searson, P. C. (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19855875 · Cited by 79
Magnetic resonance spectroscopy in the prediction of early conversion from amnestic mild cognitive impairment to dementia: a prospective cohort study
Modrego, P. J., Fayed, N. M., & Sarasa, M. (2011) · BMJ Open · doi:10.1136/bmjopen-2010-000007 · Cited by 59
The role of mutations associated with familial neurodegenerative disorders on blood–brain barrier function in an iPSC model
Katt, M. E., Mayo, L. N., Ellis, S., Mahairaki, V., Rothstein, J. D., Cheng, L., & Searson, P. C. (2019) · Fluids and Barriers of the CNS · doi:10.1186/s12987-019-0139-4 · Cited by 69
Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation
Schöll, M., Almkvist, O., Axelman, K., Stefanova, E. D., Wall, A. E., Westman, E., Långström, B., Lannfelt, L., Graff, C., & Nordberg, A. K. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.08.016 · Cited by 57
The effect of aging on brain barriers and the consequences for Alzheimer’s disease development
Gorlé, N., Cauwenberghe, C. V., Libert, C., & Vandenbroucke, R. E. (2016) · Mammalian Genome · doi:10.1007/s00335-016-9637-8 · Cited by 57
A Comprehensive View on MRI Techniques for Imaging Blood-Brain Barrier Integrity.
Elschot, E. P., Backes, W., Postma, A., van Oostenbrugge, R. V., Staals, J., Rouhl, R., & Jansen, J. (2020) · Investigative Radiology · doi:10.1097/rli.0000000000000723 · Cited by 54
Redox proteomics: understanding oxidative stress in the progression of age-related neurodegenerative disorders
Butterfield, D., & Sultana, R. (2008) · Espert Review of Proteomics · doi:10.1586/14789450.5.2.157 · Cited by 54
“Since oxidatively modified proteins are generally dysfunctional [3,5,8–10], these findings are consistent with PET studies that demonstrate decreased energy metabolism in AD and mild cognitive impairment compared with that of the control [16, 17 ].”
Identifying progressive imaging genetic patterns via multi-task sparse canonical correlation analysis: a longitudinal study of the ADNI cohort
Du, L., Liu, K., Zhu, L., Yao, X., Risacher, S. L., Guo, L., Saykin, A. J., Shen, L., & Initiative, A. D. N. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz320 · Cited by 59
Meta-analytic Comparison Between PIB-PET and FDG-PET Results in Alzheimer’s Disease and MCI
He, W., Liu, D.-H., Radua, J., Li, G., Han, B.-J., & Sun, Z.-G. (2014) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-0138-7 · Cited by 50
Impact of EEG-vigilance on brain glucose uptake measured with [18F]FDG and PET in patients with depressive episode or mild cognitive impairment
Guenther, T., Schönknecht, P., Becker, G., Olbrich, S., Sander, C., Hesse, S., Meyer, P., Luthardt, J., Hegerl, U., & Sabri, O. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.01.059 · Cited by 47
“…rights reserved. memory impairment (Anchisi et al., 2005; Baxter, Jr. et al., 1989; Chetelat et al., 2003; Drzezga et al., 2003, 2005; Dubois et al., 2007; Fouquet et al., 2009; Herholz et al., 2002; Hunt et al., 2007; Mayberg et al., 1997, 2000; Mayberg, 2003; Schonknecht et al., 2009).”
Self-citation
Neuroprotective and neurotrophic effects of long term lithium treatment in mouse brain
Riadh, N., Allagui, M., Bourogaa, E., Vincent, C., Croute, F., & Elfeki, A. (2011) · Biometals · doi:10.1007/s10534-011-9433-6 · Cited by 46
“In fact, glucose uptake and metabolism are impaired in Alzheimer disease brain and the reduction of cerebral glucose metabolism provides the earliest evidence of an ongoing neurodegenerative disease process (Hoyer 2004; Hunt et al. 2007).”
Background
Regular Exercise Enhances Cognitive Function and Intracephalic GLUT Expression in Alzheimer’s Disease Model Mice
Pang, R., Wang, X., Pei, F., Zhang, W.-Z., Shen, J., Gao, X.-Q., & Chang, C. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-190328 · Cited by 45
“Brain glucose metabolism dysregulation is one of the main features of AD [4, 5], and it is related to severity of AD pathology or symptom expression, such as cognitive impairment, accumulations of amyloid-(cid:2) (A (cid:2) ) peptide and neuroﬁbrillary tangles [6], reduced brain synapses, and…”
Bilingualism as a Contributor to Cognitive Reserve? Evidence from Cerebral Glucose Metabolism in Mild Cognitive Impairment and Alzheimer’s Disease
Kowoll, M. E., Degen, C., Gorenc, L., Küntzelmann, A., Fellhauer, I., Giesel, F., Haberkorn, U., & Schröder, J. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00062 · Cited by 45
Self-citation
MCI patients declining and not-declining at mid-term follow-up: FDG-PET findings.
Pagani, M., Dessì, B., Morbelli, S., Brugnolo, A., Salmaso, D., Piccini, A., Mazzei, D., Villavecchia, G., Larsson, S., Rodriguez, G., et al. (2010) · Current Alzheimer Research · doi:10.2174/156720510791162368 · Cited by 45
“In the majority of the studies, investigators have been looking for factors at baseline FDG-PET able to discriminate between converters and non-converters and to predict the course of the disease [2-6, 8].”
Background
Multi-Task Sparse Canonical Correlation Analysis with Application to Multi-Modal Brain Imaging Genetics
Du, L., Liu, K., Yao, X., Risacher, S., Han, J.-W., Saykin, A., Guo, L., & Shen, L. (2019) · IEEE/ACM Transactions on Computational Biology & Bioinformatics · doi:10.1109/tcbb.2019.2947428 · Cited by 44
“For example, the signiﬁcant reduction of glucose metabolism in the right angular gyrus has been observed in aging-associated cognitive decline (AACD) patients [34].”
Background
Drug Access to the Central Nervous System in Alzheimer’s Disease: Preclinical and Clinical Insights
Mehta, D. C., Short, J. L., Hilmer, S. N., & Nicolazzo, J. A. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1522-0 · Cited by 47
Diagnosis of Alzheimer’s Disease with [18F]PET in Mild and Asymptomatic Stages
Drzezga, A. (2009) · Behavioural Neurology · doi:10.3233/ben-2009-0228 · Cited by 41
Brain‐targeting drug delivery systems
Liu, P., & Jiang, C. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1818 · Cited by 47
Crucial players in Alzheimer’s disease and diabetes mellitus: Friends or foes?
Kubis-Kubiak, A., Rorbach-Dolata, A., & Piwowar, A. (2019) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2019.03.008 · Cited by 47
Age-related alteration in cerebral blood flow and energy failure is correlated with cognitive impairment in the senescence-accelerated prone mouse strain 8 (SAMP8)
Zhang, X.-Z., Li, G.-M., Guo, L., Nie, K., Jia, Y.-J., Zhao, L., & Yu, J. (2013) · Neurological Sciences · doi:10.1007/s10072-013-1407-8 · Cited by 37
“In addition to decreased CBF, the cerebral glucose transport across the BBB and the phosphorylation rates measured by FDG-PET were reduced in hypometabolic regions in MCI and AD patients [19–24].”
Background
Carbohydrates for improving the cognitive performance of independent-living older adults with normal cognition or mild cognitive impairment
Ooi, C. P., Loke, S. C., Yassin, Z., & Hamid, T.-A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007220.pub2 · Cited by 29
Alzheimer’s Disease and Porphyromonas gingivalis: Exploring the Links
Shawkatová, I., Ďurmanová, V., & Javor, J. (2025) · Life · doi:10.3390/life15010096 · Cited by 35
Prospective classification of Alzheimer’s disease conversion from mild cognitive impairment
Park, S., Hong, C. H., Lee, D. A., Park, K., & Shin, H. (2023) · Neural Networks · doi:10.1016/j.neunet.2023.04.018 · Cited by 36
“(2) PL angular gyrus L (PMID: 17524628) (Hunt et al., 2007) Compared with controls, aging-associated cognitive decline patients had significantly reduced glucose metabolism in the angular gyrus while the deficit were more pronounced in AD patients.”
Immortalised Hippocampal Astrocytes from 3xTG-AD Mice Fail to Support BBB Integrity In Vitro: Role of Extracellular Vesicles in Glial-Endothelial Communication
Kriaučiūnaitė, K., Kaušylė, A., Pajarskienė, J., Tunaitis, V., Lim, D., Verkhratsky, A., & Pivoriūnas, A. (2020) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00871-w · Cited by 40
Does hyperglycemia downregulate glucose transporters in the brain?
Leão, L. L., Tangen, G. G., Barca, M. L., Engedal, K., Santos, S. H. S., Machado, F. S. M., de Paula, A. M. B., & Monteiro-Júnior, R. S. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.109614 · Cited by 42
The Vascular-Immune Hypothesis of Alzheimer’s Disease
Mehta, R. I., & Mehta, R. I. (2023) · Biomedicines · doi:10.3390/biomedicines11020408 · Cited by 39
“18F-FDGPET imaging studies document decreased glucose uptake in specific brain regions during prodromal stages of AD [99].”
Background
Suppression of a core metabolic enzyme dihydrolipoamide dehydrogenase (dld) protects against amyloid beta toxicity in C. elegans model of Alzheimer's disease
Ahmad, W., & Ebert, P. R. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.08.004 · Cited by 37
Increased glucose metabolism and impaired glutamate transport in human astrocytes are potential early triggers of abnormal extracellular glutamate accumulation in hiPSC ‐derived models of Alzheimer's disease
Salcedo, C., Garcia, V. P., García‐Adán, B., Ameen, A. O., Gegelashvili, G., Waagepetersen, H. S., Freude, K., & Aldana, B. I. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.16014 · Cited by 30
“Reduced glucose metabolism has been detected in the majority of clinically diagnosed AD patients, which precede the onset of dementia by several years (Hunt et al., 2007 ; Mosconi, 2013 ).”
Background
Comparing standard screening questionnaires of canine behavior for assessment of cognitive dysfunction
Haake, J., Meller, S., Meyerhoff, N., Twele, F., Charalambous, M., Talbot, S., & Volk, H. A. (2024) · Frontiers in Veterinary Science · doi:10.3389/fvets.2024.1374511 · Cited by 27
“Metabolic changes in the aging brain, such as glucose hypometabolism and mitochondrial dysfunction, (4–7), and neuropathological findings, like the accumulation of ß42-amyloid plaques (8–13), and cerebral atrophy (14) may be associated with cognitive decline leading to typical clinical signs that…”
Background
Steps Towards Developing Effective Treatments for Neuropsychiatric Disturbances in Alzheimer’s Disease: Insights From Preclinical Models, Clinical Data, and Future Directions
Clement, A., Wiborg, O., & Asuni, A. A. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00056 · Cited by 28
Prediction and Modeling of Neuropsychological Scores in Alzheimer’s Disease Using Multimodal Neuroimaging Data and Artificial Neural Networks
Hojjati, S. H., Abbas Babajani-feremi, A., & Initiative, T. A. D. N. (2022) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2021.769982 · Cited by 28
“It has been reported that AD patients have signiﬁcantly reduced glucose metabolism in the angular gyrus, temporal gyrus, and posterior cingulate (Hunt et al., 2007).”
Background
Longitudinal Magnetic Resonance Spectroscopy as Marker of Cognitive Deterioration in Mild Cognitive Impairment
Modrego, P. J., & Fayed, N. M. (2011) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317511433809 · Cited by 26
“The voxel positioned in the posteromedial parietal cortex included the posterior cingulate gyrus, an area involved in early phases of AD according to PET studies.(31-33) This area is frequently explored in MRS studies and plays a pivotal role in memory as it is a part of the default mode network.”
Method
Rescue of Aβ1–42‐induced memory impairment in day‐old chick by facilitation of astrocytic oxidative metabolism: implications for Alzheimer’s disease
Gibbs, M. E., Gibbs, Z., & Hertz, L. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05800.x · Cited by 26
“2003) which can be demonstrated even in patients ‘at risk’ for developing the disease (Hunt et al. 2007).”
Background
Mitochondria in aging and age-associated diseases
Pahal, S., Mainali, N., Balasubramaniam, M., Reis, R. J. S., & Ayyadevara, S. (2025) · Mitochondrion · doi:10.1016/j.mito.2025.102022 · Cited by 32
Aging and Alzheimer’s Disease
LUPIEN, S. J., Lord, C., Sindi, S., Wilkinson, C. W., & Fiocco, A. J. (2009) · Elsevier eBooks · doi:10.1016/b978-008088783-8.00097-8 · Cited by 42
Fibrin-targeting immunotherapy for dementia
Kantor, A. B., Akassoglou, K., & Stavenhagen, J. B. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.105 · Cited by 24
“FDG-PET shows that GLUT1 levels are substantially diminished in brain micro-vessels in AD (19, 38), Moreover, imaging has revealed that patients with MCI have reduced glucose uptake in multiple brain areas prior to any apparent neurodegenerative changes, brain atrophy or conversion to AD (39, 40).”
Background
The Cerebrovascular Side of Plasticity: Microvascular Architecture across Health and Neurodegenerative and Vascular Diseases
Zedde, M., & Pascarella, R. (2024) · Brain Sciences · doi:10.3390/brainsci14100983 · Cited by 21
“Another interesting issue is related to the role of the amyloid beta (A β ) peptide in angiogenesis, which is frequently reported in the brain of AD patients in addition to neurodegeneration and neuroinflammation [152].”
Background
Nutrients, Cognitive Function, and Brain Aging: What We Have Learned from Dogs
Pan, Y. (2021) · Medical Sciences · doi:10.3390/medsci9040072 · Cited by 30
Bihemispheric Cerebral FDG PET Correlates of Cognitive Dysfunction as Assessed by the CERAD in Alzheimer's Disease
Schönknecht, O. D. P., Hunt, A. M., Toro, P., Guenther, T., Henze, M., Haberkorn, U., & Schröder, J. (2011) · Clinical EEG and Neuroscience · doi:10.1177/155005941104200207 · Cited by 20
Self-citation
Recent advances in diagnostic and therapeutic strategies for canine cognitive dysfunction
Kim, S. H., & Hao, J. (2025) · American Journal of Veterinary Research · doi:10.2460/ajvr.25.02.0053 · Cited by 14
Targeted Lipidomics of Mitochondria in a Cellular Alzheimer’s Disease Model
Kurokin, I., Lauer, A. A., Janitschke, D., Winkler, J., Theiss, E. L., Griebsch, L. V., Pilz, S. M., Matschke, V., van der Laan, M., Grimm, H. S., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9081062 · Cited by 19
5‐Methoxyindole‐2‐carboxylic acid (MICA) suppresses A&bgr;‐mediated pathology in C. elegans
Ahmad, W., & Ebert, P. (2018) · Experimental Gerontology · doi:10.1016/j.exger.2018.04.021 · Cited by 19
27-Hydroxycholesterol impairs learning and memory ability via decreasing brain glucose uptake mediated by the gut microbiota.
Hao, L., Wang, L., Ju, M., Feng, W., Guo, Z., Sun, X., & Xiao, R. (2023) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2023.115649 · Cited by 18
Hypoperfusion is a potential inducer of immunosuppressive network in Alzheimer's disease
Salminen, A. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104919 · Cited by 20
Fast Multi-Task SCCA Learning with Feature Selection for Multi-Modal Brain Imaging Genetics
Du, L., Liu, K., Yao, X., Risacher, S., Han, J.-W., Guo, L., Saykin, A., & Shen, L. (2018) · IEEE International Conference on Bioinformatics and Biomedicine · doi:10.1109/bibm.2018.8621298 · Cited by 18
“Most importantly, these markers are all have been documented to be related to AD or MCI [21]–[25].”
BackgroundInfluential
Detecting dementia from written and spoken language
Masrani, V. (2018) · cIRcle (University of British Columbia) · doi:10.14288/1.0362923 · Cited by 18
“cortices) which can add evidence towards a diagnosis [24, 33, 60].”
Background
Is blood-brain barrier a probable mediator of non-invasive brain stimulation effects on Alzheimer’s disease?
Petrovskaya, A. V., Tverskoi, A. M., Medvedeva, A., & Nazarova, M. A. (2023) · Communications Biology · doi:10.1038/s42003-023-04717-1 · Cited by 21
Cooperation of cell adhesion and autophagy in the brain: Functional roles in development and neurodegenerative disease
Hernandez, S. J., Fote, G., Reyes-Ortiz, A. M., Steffan, J. S., & Thompson, L. M. (2021) · Matrix Biology Plus · doi:10.1016/j.mbplus.2021.100089 · Cited by 17
“Patients with Alzheimer’s and Parkinson’s have reduced glucose transport [57,250,251] and the reduced ability to remove pharmaceuticals and xenobiotics via 15”
Background
Predicting progression of amnesic MCI: The integration of episodic memory impairment with perfusion SPECT
Quaranta, D., Gainotti, G., Giuda, D. D., Vita, M. G., Cocciolillo, F., Lacidogna, G., Guglielmi, V., Masullo, C., Giordano, A., & Marra, C. (2017) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2017.10.008 · Cited by 17
The Role of Astrocytes and Blood–Brain Barrier Disruption in Alzheimer’s Disease
Cruz, J. V. R., Batista, C., Diniz, L. P., & Mendes, F. A. (2023) · Neuroglia · doi:10.3390/neuroglia4030015 · Cited by 20
“…hypoplasia The glucose transporter GLUT1 is also downregulated in AD brain ECs, causing decreased glucose uptake and LRP1 downregulation via sterol-binding protein-2 (SREBP2)-dependent transcription, resulting in A β accumulation [36]. and less LRP1-mediated Aβ clearance from the brain [35] .”
Background
ApoE: The link between Alzheimer’s-related glucose hypometabolism and Aβ deposition?
Patil, S. P., Ballard, R., Sanchez, S., Osborn, J., & Santangelo, D. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.01.015 · Cited by 13
(18F)FDG-PET as a Biomarker for Early Alzheimer's Disease
Nobili, F., & Morbelli, S. (2010) · The Open Nuclear Medicine Journal · doi:10.2174/1876388x01002010046 · Cited by 13
Neural correlates of delayed episodic memory in patients with mild cognitive impairment--a FDG PET study.
Schönknecht, O. D. P., Hunt, A. M., Toro, P., Henze, M., Haberkorn, U., & Schröder, J. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.10.014 · Cited by 13
Self-citation

Authors: Hunt, A., Schönknecht, P., Henze, M., Seidl, U., Haberkorn, U., & Schröder, J.
Affiliations: Heidelberg University (DE)
German Cancer Research Center (DE)
Corresponding author: Schröder, Johannes
ORCID: Schröder, Johannes
Venue: Psychiatry Research: Neuroimaging
Publisher: Elsevier BV
Published: 2007-07
Volume: 155
Issue: 2
Pages: 147-154
ISSN: 0925-4927 (ISSN-L)
DOI: 10.1016/j.pscychresns.2006.12.003
OpenAlex: W2037603765
Cited by: 146
References: 41
Citations by year: 2026: 4 · 2025: 6 · 2024: 9 · 2023: 16 · 2022: 5 · 2021: 9 · 2020: 6 · 2019: 9 · 2018: 9 · 2017: 7 · 2016: 10 · 2015: 5 · 2014: 5 · 2013: 4 · 2012: 8
FWCI: 4.03
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Psychiatry Research Neuroimaging (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords: Alzheimer's disease, brain glucose metabolism, mild cognitive impairment, conversion to Alzheimer's disease, precuneus, posterior cingulate cortex, angular gyrus, middle temporal cortex, frontal cortex, thalamus, FDG-PET
MeSH terms: Aged, Alzheimer Disease, Brain, Brain Mapping, Cerebral Cortex, Cognition Disorders, Female, Follow-Up Studies, Frontal Lobe, Glucose, Gyrus Cinguli, Humans, Image Processing, Computer-Assisted, Functional Laterality, Male, Severity of Illness Index, Temporal Lobe, Tissue Distribution, Disease Progression, Fluorodeoxyglucose F18, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Metadata

Record

About these checks